Gene therapy of cardiovascular disease.
Coronary and peripheral artery diseases are highly prevalent and characterized by an unmet requirement for medical treatment in the more advanced stages. These shortcomings comprise the requirement for vessel regeneration using therapeutic angiogenesis as well as the prevention of post-angioplasty restenosis using local gene therapy. Both therapeutic angiogenesis and gene therapy to prevent post-angioplasty restenosis have undergone extensive research in the past 17 years and have led to a number of phase II clinical trials and a phase III approval trial. The development of therapeutic strategies based on gene therapy over the last 7 years is reviewed, including data from animal studies as well as phase II clinical trials.
Nikol
Sigrid
S
University Hospital Münster, Medizinische Klinik und Poliklinik C, Department of Cardiology and Angiology, Münster, Germany. nikol@uni-muenster.de
D002318:Cardiovascular Diseases / Q000235:genetics / Q000628:therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015316:Genetic Therapy / Q000379:methods*; D006083:Graft Occlusion, Vascular / Q000235:genetics / Q000517:prevention & control*; D006801:Humans; D018919:Neovascularization, Physiologic / Q000235:genetics